↓ Skip to main content

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

Overview of attention for article published in Clinical Pharmacology & Therapeutics, January 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
10 tweeters
facebook
1 Facebook page
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
343 Dimensions

Readers on

mendeley
304 Mendeley
Title
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
Published in
Clinical Pharmacology & Therapeutics, January 2013
DOI 10.1038/clpt.2013.2
Pubmed ID
Authors

J K Hicks, J J Swen, C F Thorn, K Sangkuhl, E D Kharasch, V L Ellingrod, T C Skaar, D J Müller, A Gaedigk, J C Stingl

Abstract

Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 304 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 1%
United Kingdom 1 <1%
India 1 <1%
France 1 <1%
Unknown 297 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 55 18%
Student > Bachelor 44 14%
Student > Ph. D. Student 43 14%
Student > Master 37 12%
Other 28 9%
Other 70 23%
Unknown 27 9%
Readers by discipline Count As %
Medicine and Dentistry 94 31%
Biochemistry, Genetics and Molecular Biology 49 16%
Agricultural and Biological Sciences 49 16%
Pharmacology, Toxicology and Pharmaceutical Science 47 15%
Neuroscience 6 2%
Other 25 8%
Unknown 34 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2015.
All research outputs
#1,779,038
of 14,054,251 outputs
Outputs from Clinical Pharmacology & Therapeutics
#335
of 3,060 outputs
Outputs of similar age
#20,328
of 148,757 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#7
of 32 outputs
Altmetric has tracked 14,054,251 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,060 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 148,757 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.